P. Ho, C. Bryson, and J. Rumsfeld, Medication Adherence: Its Importance in Cardiovascular Outcomes, Circulation, vol.119, issue.23, pp.3028-3063, 2009.
DOI : 10.1161/CIRCULATIONAHA.108.768986

Q. Gu, C. Dillon, and V. Burt, Prescription drug use continues to increase: US prescription drug data for, NCHS Data Brief, vol.42, pp.1-8, 2007.

M. Volpe, D. Chin, and F. Paneni, The challenge of polypharmacy in cardiovascular medicine, Fundamental & Clinical Pharmacology, vol.16, issue.1, pp.9-17, 2010.
DOI : 10.1111/j.1532-5415.1988.tb04395.x

G. Mancia, D. Backer, G. Dominiczak, A. Cifkova, R. Fagard et al., 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension, Journal of Hypertension, vol.25, issue.9, pp.1751-62, 2007.
DOI : 10.1097/HJH.0b013e3282f0580f

N. Stone, J. Robinson, A. Lichtenstein, B. Merz, C. Blum et al., AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, vol.6325, pp.2889-934, 2014.

/. Authors, M. Task-force, L. Ryden, P. Grant, S. Anker et al., ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD), Eur Heart J, vol.34, issue.39, pp.3035-87, 2013.

T. Jörgensen, S. Johansson, A. Kennerfalk, M. Wallander, and K. Svärdsudd, Prescription Drug Use, Diagnoses, and Healthcare Utilization among the Elderly, Annals of Pharmacotherapy, vol.8, issue.9, pp.1004-1013, 2001.
DOI : 10.3109/02813438809009297

S. Haider, K. Johnell, M. Thorslund, and J. Fastbom, Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992 ?? 2002, Int. Journal of Clinical Pharmacology and Therapeutics, vol.45, issue.12, pp.643-53, 2007.
DOI : 10.5414/CPP45643

D. Kaufman, J. Kelly, L. Rosenberg, T. Anderson, and A. Mitchell, Recent Patterns of Medication Use in the Ambulatory Adult Population of the United States, JAMA, vol.287, issue.3, pp.337-381, 2002.
DOI : 10.1001/jama.287.3.337

E. Hajjar, A. Cafiero, and J. Hanlon, Polypharmacy in elderly patients, The American Journal of Geriatric Pharmacotherapy, vol.5, issue.4, pp.345-51, 2007.
DOI : 10.1016/j.amjopharm.2007.12.002

R. Holman, A. Farmer, M. Davies, J. Levy, J. Darbyshire et al., Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes, New England Journal of Medicine, vol.361, issue.18, pp.1736-1783, 2009.
DOI : 10.1056/NEJMoa0905479

M. Brod, P. Valensi, J. Shaban, D. Bushnell, and T. Christensen, Patient treatment satisfaction after switching to NovoMix?? 30 (BIAsp 30) in the IMPROVE??? study: an analysis of the influence of prior and current treatment factors, Quality of Life Research, vol.62, issue.11, pp.1285-93, 2010.
DOI : 10.1007/s11136-010-9699-0

G. Reach, L. Pautremat, V. Gupta, and S. , Determinants and consequences of insulin initiation for type 2 diabetes in France: analysis of the National Health and Wellness Survey, Patient Preference and Adherence, vol.7, pp.1007-1030, 2013.
DOI : 10.2147/PPA.S51299

A. Garber, M. Abrahamson, J. Barzilay, L. Blonde, Z. Bloomgarden et al., AACE Comprehensive Diabetes Management Algorithm 2013, Endocrine Practice, vol.19, issue.2, pp.327-363, 2013.
DOI : 10.4158/endp.19.2.a38267720403k242

M. Davies and J. Speight, Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus, Diabetes, Obesity and Metabolism, vol.41, issue.Suppl. 1, pp.882-92, 2012.
DOI : 10.1097/01.MLR.0000062554.74615.4C

C. Bradley, Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur, Diabetes Care, vol.22, issue.3, p.530, 1999.
DOI : 10.2337/diacare.22.3.530

D. Drucker, J. Buse, K. Taylor, D. Kendall, M. Trautmann et al., Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study, The Lancet, vol.372, issue.9645, pp.1240-50, 2008.
DOI : 10.1016/S0140-6736(08)61206-4

J. Buse, J. Rosenstock, G. Sesti, W. Schmidt, E. Montanya et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), The Lancet, vol.374, issue.9683, pp.39-47, 2009.
DOI : 10.1016/S0140-6736(09)60659-0

J. Buse, G. Sesti, W. Schmidt, E. Montanya, C. Chang et al., Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents, Diabetes Care, vol.33, issue.6, pp.1300-1303, 2010.
DOI : 10.2337/dc09-2260

G. Norman, J. Sloan, and K. Wyrwich, Interpretation of Changes in Health-related Quality of Life, Medical Care, vol.41, issue.5, pp.582-92, 2003.
DOI : 10.1097/01.MLR.0000062554.74615.4C

S. Johnston, H. Nguyen, E. Felber, K. Cappell, J. Nelson et al., Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States, Advances in Therapy, vol.29, issue.5, pp.311119-311152, 2014.
DOI : 10.1185/03007995.2013.821056

L. Zhang, A. Zakharyan, K. Stockl, A. Harada, B. Curtis et al., Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes, Journal of Medical Economics, vol.14, issue.5, pp.562-569, 2011.
DOI : 10.3111/13696998.2011.598200

A. Hauber, H. Nguyen, J. Posner, C. Ervin, S. Larue et al., Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetes, ISPOR 19th Annual International Meeting, 2014.
DOI : 10.1016/j.jval.2014.03.1488

K. Hermansen, R. Kolotkin, M. Hammer, M. Zdravkovic, and D. Matthews, Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin, Primary Care Diabetes, vol.4, issue.2, pp.113-120, 2010.
DOI : 10.1016/j.pcd.2010.04.001

J. Best, R. Rubin, M. Peyrot, Y. Li, P. Yan et al., Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment, Diabetes Care, vol.34, issue.2, pp.314-323, 2011.
DOI : 10.2337/dc10-1119

R. Pratley, M. Nauck, T. Bailey, and L. Group, Switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide further improves glycemic control and weight loss in patients with type 2 diabetes, Diabetes, vol.60, issue.1, pp.307-315, 2011.

E. Montanya, R. Pratley, M. Nauck, T. Bailey, A. Garber et al., Switching from sitagliptin to liraglutide , in combination with metformin, improves treatment satisfaction in patients with type 2 diabetes, Diabetes, vol.60, p.307, 2011.

B. Zinman, J. Lachin, and S. Inzucchi, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, New England Journal of Medicine, vol.373, issue.22, p.1094, 2016.
DOI : 10.1056/NEJMoa1504720

M. Pfeffer, B. Claggett, R. Diaz, K. Dickstein, H. Gerstein et al., Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome, New England Journal of Medicine, vol.373, issue.23, pp.2247-57, 2015.
DOI : 10.1056/NEJMoa1509225
URL : http://www.zora.uzh.ch/119538/1/Lixisenatide%20in%20pts.pdf

O. Investigators, H. Gerstein, J. Bosch, G. Dagenais, R. Diaz et al., Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia, New England Journal of Medicine, vol.367, issue.4, pp.319-347, 2012.
DOI : 10.1056/NEJMoa1203858

D. Nathan, Rosiglitazone and Cardiotoxicity ??? Weighing the Evidence, New England Journal of Medicine, vol.357, issue.1, pp.64-70, 2007.
DOI : 10.1056/NEJMe078117

K. Krobot, D. Yin, E. Alemao, and E. Steinhagen-thiessen, Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart

Z. Reiner, Resistance and intolerance to statins, Nutrition, Metabolism and Cardiovascular Diseases, vol.24, issue.10, pp.1057-66, 2014.
DOI : 10.1016/j.numecd.2014.05.009

H. Superko, K. Momary, and Y. Li, Statins Personalized, Medical Clinics of North America, vol.96, issue.1, pp.123-162, 2012.
DOI : 10.1016/j.mcna.2011.11.004

N. Stone, Reducing Residual Risk in Secondary Prevention of Cardiovascular Disease, Circulation, vol.125, issue.16, pp.1958-60, 2012.
DOI : 10.1161/CIRCULATIONAHA.112.101782

A. Pirillo and A. Catapano, Statin Intolerance: Diagnosis and Remedies, Current Cardiology Reports, vol.11, issue.5, p.27, 2015.
DOI : 10.1186/1476-511X-11-123

C. Cannon, M. Blazing, R. Giugliano, A. Mccagg, J. White et al., Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes, New England Journal of Medicine, vol.372, issue.25, pp.2387-97, 2015.
DOI : 10.1056/NEJMoa1410489
URL : https://hal.archives-ouvertes.fr/hal-01258957

J. Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc et al., Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events, New England Journal of Medicine, vol.372, issue.16, pp.1489-99, 2015.
DOI : 10.1056/NEJMoa1501031

M. Sabatine, R. Giugliano, S. Wiviott, F. Raal, D. Blom et al., Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events, New England Journal of Medicine, vol.372, issue.16, pp.1500-1509, 2015.
DOI : 10.1056/NEJMoa1500858

R. Dent, R. Joshi, C. Djedjos, J. Legg, M. Elliott et al., Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting, SpringerPlus, vol.63, issue.1, p.1, 2016.
DOI : 10.1016/j.jacc.2014.03.019

A. Kiyosue, N. Honarpour, C. Kurtz, A. Xue, S. Wasserman et al., A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk, The American Journal of Cardiology, vol.117, issue.1, pp.40-47, 2016.
DOI : 10.1016/j.amjcard.2015.10.021

M. Koren, P. Lundqvist, M. Bolognese, J. Neutel, M. Monsalvo et al., Anti-PCSK9 Monotherapy for Hypercholesterolemia, Journal of the American College of Cardiology, vol.63, issue.23, pp.2531-2571, 2014.
DOI : 10.1016/j.jacc.2014.03.018
URL : http://doi.org/10.1016/j.jacc.2014.03.018

F. Raal, E. Stein, R. Dufour, T. Turner, F. Civeira et al., PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, The Lancet, vol.385, issue.9965, pp.331-371, 2015.
DOI : 10.1016/S0140-6736(14)61399-4

E. Stroes, D. Colquhoun, D. Sullivan, F. Civeira, R. Rosenson et al., Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance, Journal of the American College of Cardiology, vol.63, issue.23, pp.2541-2549, 2014.
DOI : 10.1016/j.jacc.2014.03.019

A. European-medicines, Repatha (evolocumab ): EU summary of product characteristics, 2016.

A. European-medicines, Praluent (alirocumab): EU summary of product characteristics. 2016. Accessed Available at, 2016.

A. Investigators, W. Boden, J. Probstfield, T. Anderson, B. Chaitman et al., Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy, New England Journal of Medicine, vol.365, issue.24, pp.2255-67, 2011.
DOI : 10.1056/NEJMoa1107579

H. Group, HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stop- ping study treatment, Eur Heart J, vol.34, issue.17, pp.1279-91, 2013.

A. Group, H. Ginsberg, M. Elam, L. Lovato, J. Crouse et al., Effects of combination lipid therapy in type 2 diabetes mellitus, N Engl J Med, vol.362, issue.17, pp.1563-74, 2010.

A. Keech, R. Simes, P. Barter, J. Best, R. Scott et al., We-S15:2 Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: The field study, a randomised controlled trial, Atherosclerosis Supplements, vol.7, issue.3, pp.1849-61, 2005.
DOI : 10.1016/S1567-5688(06)81349-8

T. Jacobson, M. Ito, K. Maki, C. Orringer, H. Bays et al., National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 ??? executive summary, Journal of Clinical Lipidology, vol.8, issue.5, pp.473-88, 2014.
DOI : 10.1016/j.jacl.2014.07.007

C. Writing, L. , D. Morris, P. Ballantyne, C. Birtcher et al., 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of cardiology task force on clinical expert consensus documents, J Am Coll Cardiol, vol.68, issue.1, pp.92-125, 2016.

V. Sathiyakumar, S. Martin, S. Jones, J. Quinn, R. Green et al., Real-World PCSK9i Experience: the Importance of a Multidisciplinary Approach, Journal of Clinical Lipidology, vol.11, issue.3, p.803, 2017.
DOI : 10.1016/j.jacl.2017.04.052

U. Fda, Drug Databases (approved drug products) Repatha (evolocumab) Highlights of prescribing information [BLA 125522 Available at, 2016.

M. Sabatine, R. Giugliano, A. Keech, N. Honarpour, S. Wiviott et al., Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, New England Journal of Medicine, vol.376, issue.18, pp.1713-1735, 2017.
DOI : 10.1056/NEJMoa1615664

E. Stein, R. Giugliano, M. Koren, F. Raal, E. Roth et al., Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials, European Heart Journal, vol.35, issue.33, pp.2249-59, 2014.
DOI : 10.1093/eurheartj/ehu085

J. Robinson, B. Nedergaard, W. Rogers, J. Fialkow, J. Neutel et al., Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia, JAMA, vol.311, issue.18, pp.3111870-83, 2014.
DOI : 10.1001/jama.2014.4030
URL : https://hal.archives-ouvertes.fr/hal-01256982

M. Koren, C. Djedjos, Y. Ma, R. Somaratne, and M. Bolognese, THE OSLER-2 STUDY: PATIENTS??? PREFERENCES AND COMPLIANCE WITH BIWEEKLY OR MONTHLY DOSING DURING TREATMENT OF HYPERCHOLESTEROLEMIA WITH EVOLOCUMAB, Journal of the American College of Cardiology, vol.67, issue.13, 1995.
DOI : 10.1016/S0735-1097(16)31996-9

D. Blom, T. Hala, M. Bolognese, M. Lillestol, P. Toth et al., A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia, New England Journal of Medicine, vol.370, issue.19, pp.1809-1828, 2014.
DOI : 10.1056/NEJMoa1316222

E. Stein, M. Koren, N. Honarpour, C. Kurtz, Y. J. Wasserman et al., CLINICAL EQUIVALENCE OF EVOLOCUMAB 140 MG EVERY TWO WEEKS AND 420 MG MONTHLY DOSING REGIMENS: A POOLED ANALYSIS OF 3146 PATIENTS IN PHASE 3 STUDIES, Journal of the American College of Cardiology, vol.65, issue.10, 2015.
DOI : 10.1016/S0735-1097(15)61368-7

U. Fda, Drug Databases (approved drug products) Repatha (evolocumab) Supplemental approval letter 2016, BLA, vol.125522, 2016.

U. Fda, Drug Databases (approved drug products) Praluent (alirocumab) Highlights of prescribing information [BLA 125559 Available at, 2016.

M. Farnier, H. Colhoun, W. Sasiela, J. Edelberg, G. Asset et al., Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 ??? 104 weeks, Presented at 84th EAS Congress 2016, Austria. OT05 Workshop (Late Breaking
DOI : 10.1016/j.atherosclerosis.2016.07.070

K. Ray, U. Landmesser, L. Leiter, D. Kallend, R. Dufour et al., Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol, New England Journal of Medicine, vol.376, issue.15, pp.1430-1470, 2017.
DOI : 10.1056/NEJMoa1615758